Literature DB >> 11489366

Fosfomycin nebulizer therapy to chronic sinusitis.

A Kamijyo1, Z Matsuzaki, K Kikushima, J Ogino, I Nozawa, T Matsuoka, S Endo, Y Okamoto.   

Abstract

OBJECTIVE: effects of Fosfomycin (FOM) nebulizer therapy were studied in patients with chronic sinusitis.
METHODS: about 28 patients with chronic sinusitis were administered 2 ml of FOM sodium (3% w/v) by nebulizer three times per week for 4 weeks. Levels of IL-1 beta, IL-6, IL-8, and TNF-alpha in nasal lavage were also measured before and at the end of treatment.
RESULTS: the overall efficacy of this treatment on the basis of both subjective and objective symptoms, was 'excellent' for 28.6%, 'good' for 10.7%, 'fair' for 39.4%, and yield 'no change' for 21.4% of the patients. Both IL-1 beta and IL-6 concentrations were significantly decreased after treatment. Although the IL-8 level did not significantly decrease, it seems to be related to the overall efficacy. TNF-alpha was not detected in all of the samples.
CONCLUSION: FOM nebulization therapy is highly effective in treatment for chronic sinusitis, and efficacy may be due to an immunomodulatory mechanism, as well as its bactericidal effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489366     DOI: 10.1016/s0385-8146(01)00049-9

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  4 in total

Review 1.  Update on Intranasal Medications in Rhinosinusitis.

Authors:  Kornkiat Snidvongs; Sanguansak Thanaviratananich
Journal:  Curr Allergy Asthma Rep       Date:  2017-07       Impact factor: 4.806

2.  Antimicrobial therapy in chronic rhinosinusitis.

Authors:  Neil Bhattacharyya
Journal:  Curr Allergy Asthma Rep       Date:  2009-05       Impact factor: 4.806

3.  Survey of nebulizer therapy for nasal inflammatory diseases in Japan before and during the COVID-19 pandemic.

Authors:  Yukiyoshi Hyo; Shigeharu Fujieda; Atsushi Matsubara; Kazuhiko Takeuchi; Motofumi Ohki; Takeshi Shimizu; Yuichi Kurono
Journal:  Auris Nasus Larynx       Date:  2021-11-22       Impact factor: 2.119

Review 4.  Novel drug-delivery systems for patients with chronic rhinosinusitis.

Authors:  Silviu Albu
Journal:  Drug Des Devel Ther       Date:  2012-05-31       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.